CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice L Xu, KH Park, L Zhao, J Xu, M El Refaey, Y Gao, H Zhu, J Ma, R Han Molecular Therapy 24 (3), 564-569, 2016 | 280 | 2016 |
In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice M El Refaey, L Xu, Y Gao, BD Canan, TMA Adesanya, SC Warner, ... Circulation research 121 (8), 923-929, 2017 | 151 | 2017 |
The intracellular Ca2+ channel MCOLN1 is required for sarcolemma repair to prevent muscular dystrophy X Cheng, X Zhang, Q Gao, M Ali Samie, M Azar, WL Tsang, L Dong, ... Nature medicine 20 (10), 1187-1192, 2014 | 130 | 2014 |
Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA L Xu, L Zhao, Y Gao, J Xu, R Han Nucleic acids research 45 (5), e28-e28, 2017 | 110 | 2017 |
A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9 T Sui, YS Lau, D Liu, T Liu, L Xu, Y Gao, L Lai, Z Li, R Han Disease models & mechanisms 11 (6), dmm032201, 2018 | 95 | 2018 |
Efficient precise in vivo base editing in adult dystrophic mice L Xu, C Zhang, H Li, P Wang, Y Gao, NA Mokadam, J Ma, WD Arnold, ... Nature communications 12 (1), 3719, 2021 | 91 | 2021 |
Life-long AAV-mediated CRISPR genome editing in dystrophic heart improves cardiomyopathy without causing serious lesions in mdx mice L Xu, YS Lau, Y Gao, H Li, R Han Molecular Therapy 27 (8), 1407-1414, 2019 | 51 | 2019 |
MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer H Li, PH Lin, P Gupta, X Li, SL Zhao, X Zhou, Z Li, S Wei, L Xu, R Han, ... Molecular cancer 20, 1-15, 2021 | 49 | 2021 |
Genetic disruption of Ano5 in mice does not recapitulate human ANO5-deficient muscular dystrophy J Xu, M El Refaey, L Xu, L Zhao, Y Gao, K Floyd, T Karaze, PML Janssen, ... Skeletal muscle 5, 1-14, 2015 | 49 | 2015 |
Automated muscle histopathology analysis using CellProfiler YS Lau, L Xu, Y Gao, R Han Skeletal muscle 8, 1-9, 2018 | 47 | 2018 |
Targeted myostatin gene editing in multiple mammalian species directed by a single pair of TALE nucleases L Xu, P Zhao, A Mariano, R Han Molecular Therapy-Nucleic Acids 2, 2013 | 46 | 2013 |
Dysferlin forms a dimer mediated by the C2 domains and the transmembrane domain in vitro and in living cells L Xu, S Pallikkuth, Z Hou, GA Mignery, SL Robia, R Han PloS one 6 (11), e27884, 2011 | 42 | 2011 |
BEAT: a Python program to quantify base editing from sanger sequencing L Xu, Y Liu, R Han The CRISPR journal 2 (4), 223-229, 2019 | 34 | 2019 |
Studies on preparation and photodynamic mechanism of chlorin P6-13, 15-N-(cyclohexyl) cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo Y Yan, M Zheng, Z Chen, X Yu, X Yang, Z Ding, L Xu Bioorganic & medicinal chemistry 18 (17), 6282-6291, 2010 | 32 | 2010 |
Anoctamin 6 regulates C2C12 myoblast proliferation P Zhao, A Torcaso, A Mariano, L Xu, S Mohsin, L Zhao, R Han PLoS One 9 (3), e92749, 2014 | 28 | 2014 |
BEON: a functional fluorescence reporter for quantification and enrichment of adenine base-editing activity P Wang, L Xu, Y Gao, R Han Molecular Therapy 28 (7), 1696-1705, 2020 | 22 | 2020 |
Highly efficient genome editing via 2A-coupled co-expression of two TALEN monomers A Mariano, L Xu, R Han BMC research notes 7, 1-5, 2014 | 15 | 2014 |
A novel ANO5 splicing variant in a LGMD2L patient leads to production of a truncated aggregation‐prone Ano5 peptide J Xu, L Xu, YS Lau, Y Gao, SA Moore, R Han The Journal of Pathology: Clinical Research 4 (2), 135-145, 2018 | 10 | 2018 |
Equal force recovery in dysferlin‐deficient and wild‐type muscles following saponin exposure P Zhao, L Xu, Y Ait-Mou, PP De Tombe, R Han BioMed Research International 2011 (1), 235216, 2011 | 9 | 2011 |
BVES is a novel interactor of ANO5 and regulates myoblast differentiation H Li, L Xu, Y Gao, Y Zuo, Z Yang, L Zhao, Z Chen, S Guo, R Han Cell & Bioscience 11, 1-10, 2021 | 8 | 2021 |